Acrivon Therapeutics, Inc. ACRV 深 沪
交易中 10-16 10:27:35 美东时间
1.98
+0.090
+4.76%
华盛通- 最 高1.9807
- 今 开1.90
- 成交量 9.68万股
- 最 低 1.90
- 昨 收 1.89
- 总市值 6228.21万
- 52周最高 8.74
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 1.05
- 委 比 -16.86%
- 总股本 3145.56万
- 历史最高 25.47
- 量 比 1.94
- 振 幅 4.27%
- 历史最低 1.05
- 每 手 1
- 风险率 2.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics granted equity awards in the form of stock options to an employee under its 2023 Inducement Plan. The options, totaling 225,000 shares, vest over four years with 25% after the first anniversary and monthly installments thereafter. Acrivon, a biotech company leveraging its proprietary Generative Phosphoproteomics AP3 platform, is advancing precision medicines, including ACR-368 in a Phase 2 trial for endometrial cancer and ACR...
10-01 20:30
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Shares of Robinhood Markets, Inc. (NASDAQ:HOOD) rose sharply in pre-market trad...
09-08 17:30
Acrivon Therapeutics Highlights Synergy in Updated Presentation
An update from Acrivon Therapeutics, Inc. ( ($ACRV) ) is now available. On Sept...
09-06 04:47
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Jazz Pharmaceuticals (JAZZ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-28 17:50
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Oppenheimer Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $8
Oppenheimer analyst Matthew Biegler maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price target from $9 to $8.
08-15 02:08
Acrivon Therapeutics Q2 EPS $(0.55) Beats $(0.58) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.58) by 5.98 percent. This is a 5.77 percent decrease over losses of $(0.52) per share
08-14 04:17
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Acrivon Therapeutics reported Q2 2025 financial results with a net loss of $21.0 million and cash reserves of $147.6 million. The company advanced its lead asset ACR-368 in endometrial cancer and initiated a new Phase 2b study arm. ACR-2316 demonstrated initial clinical activity in solid tumor types. The Generative Phosphoproteomics AP3 platform enabled pathway-based drug design. Acrivon expects to report updates on ACR-368 and ACR-2316 in 2025.
08-13 20:15
Jones Trading Downgrades Acrivon Therapeutics to Hold
Jones Trading analyst Soumit Roy downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Hold.
05-17 04:33
Acrivon Therapeutics Q1 EPS $(0.51) Beats $(0.66) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.66) by 22.73 percent. This is a 30.14 percent increase over losses of $(0.73) per share
05-15 04:28
